Clinical Scorecard: In Memoriam: Prof. Jon van Rood (1926–2017)

At a Glance

Key Highlights

• Prof. Jon van Rood was a founding member of EBMT and key founder of BMDW and WMDA, shaping global cooperation in unrelated hematopoietic stem cell transplantation.
• He discovered HLA antibodies in the 1950s and pioneered the use of computers to analyze serological reactions, identifying early HLA alleles.
• His work on the immune repertoire of mothers and children influenced understanding of transplantation outcomes and opened therapeutic options for thousands of patients.

Guideline-Based Recommendations

Diagnosis

• Utilize HLA typing for donor-recipient matching in transfusion and transplantation medicine.

Management

• Incorporate knowledge of inherited paternal and noninherited maternal antigens to optimize hematopoietic cell transplantation outcomes.

Monitoring & Follow-up

• Monitor immune responses post-transplantation considering maternal and paternal antigen influences.

Risks

• Recognize alloimmunization risks induced by pregnancy-related leukocyte antibodies.

Patient & Prescribing Data

Patients undergoing hematopoietic stem cell transplantation, particularly leukemia patients

HLA matching and understanding of immune repertoires improve transplantation success and reduce complications.

Clinical Best Practices

• Apply advanced HLA typing techniques for donor selection.
• Consider maternal and paternal antigen effects in transplantation immunology.
• Promote international collaboration for donor registries and transplantation standards.

References

• European Society for Blood and Marrow Transplantation (EBMT) In Memoriam: Prof. Jon van Rood
• Leslie Brent, A History of Transplantation Immunology